Pasithea Therapeutics Corp.
KTTA
$1.16
-$0.03-2.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.12% | 4.73% | -14.92% | -2.65% | -34.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.51% | -3.89% | -8.94% | -36.69% | -20.71% |
| Operating Income | -3.51% | 3.89% | 8.94% | 36.69% | 20.71% |
| Income Before Tax | -1.25% | 3.88% | 7.71% | 36.84% | 16.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.25% | 3.88% | 7.71% | 36.84% | 16.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.25% | 3.88% | 7.71% | 37.05% | 16.96% |
| EBIT | -3.51% | 3.89% | 8.94% | 36.69% | 20.71% |
| EBITDA | -3.03% | 4.05% | 9.30% | 37.89% | 21.64% |
| EPS Basic | 85.80% | 82.22% | 56.49% | 44.30% | -0.05% |
| Normalized Basic EPS | 85.80% | 82.22% | 56.50% | 43.91% | -0.05% |
| EPS Diluted | 85.80% | 82.22% | 56.49% | 44.30% | -0.05% |
| Normalized Diluted EPS | 85.80% | 82.22% | 56.50% | 43.91% | -0.05% |
| Average Basic Shares Outstanding | 612.92% | 440.72% | 112.11% | 2.27% | -17.01% |
| Average Diluted Shares Outstanding | 612.92% | 440.72% | 112.11% | 2.27% | -17.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |